Cancer presents a global challenge. With over 17 million new cases of cancer worldwide in 2018 and 9.6 million deaths in the same year, better approaches to the prevention, diagnosis and treatment of cancer are urgently required.

Founded in 1979, Worldwide Cancer Research is a UK-based charity dedicated to meeting these needs by starting new cancer cures worldwide. In this exclusive interview, we speak again with Worldwide Cancer Research’s Chief Executive, Dr Helen Rippon, to hear about their recent efforts and plans for the future.

We last spoke in early 2019. A lot has happened over the past two years! What are the current priorities and focus for Worldwide Cancer Research?

2019 marked our 40-year anniversary and because it was such a significant milestone for us, we wanted to take the opportunity to reflect on what we have achieved since we were founded in 1979, reaffirm our mission as a charity and really focus on our vision for the future.

As a result, we went through a lot of changes as an organisation – we relocated from our original home in St Andrews to Edinburgh, recruited new team members and rebranded to reach new supporters and better represent Worldwide Cancer Research today.

But despite all the changes, our core mission and values have remained the same. We are still the only charity in the UK dedicated to starting new cancer cures by funding discovery research all over the world.

We are still confident in the power of people and the human mind. We know that we can make a real impact when we come together with a single goal in mind – to end cancer.

Each year our panel of scientific experts from around the world come together at our Big Ideas Gathering to decide which new cancer research projects to fund. And each year we receive an incredible number of applications but we are currently only able to offer funding to around 20% of the applications that could lead to new cures in the future.

That’s why our one big priority is to be able to fund more lifesaving cancer research. Specifically, we want to be able to fund £20million of research annually by 2030. Currently, we fund an average of £4million a year, so there’s a lot of work for us to do. And we can’t do it alone – we need many more people to join us and become Curestarters.

What do you mean exactly when you talk about becoming a Curestarter?

We know that the research journey is a long one and that it can take up to 20 years for an idea to lead to new treatments. But we also know that there can’t be an end to cancer if we don’t start at the beginning.

And we couldn’t start any new cancer cures without our amazing supporters. We don’t receive any government funding, so we’re entirely reliant on the kindness and generosity of the people who raise much-needed awareness and money for us – whether that’s by setting up a Direct Debit, playing our Weekly Lottery, fundraising with family and friends or any number of other options – they are all Curestarters.

It is often asked ‘why isn’t there a cure for cancer yet?’. What is your response to that?

Cancer is complex and the more we learn about it, the more it becomes clear that there won’t ever be a ‘magic bullet’. To understand why, the most important thing to know is that cancer is not one disease. Instead, it’s an umbrella term for more than 200 distinct diseases. Each broad cancer type also has many subtypes, and they all look and behave differently because they are different on a genetic and molecular level. This is because cancer arises from our own cells, so each cancer can be as different and diverse as people are. And that means that there isn’t ever going to be a one-shot cure-all for cancer.

But that doesn’t mean that there hasn’t been incredible progress made. Thanks to research like the projects funded by Worldwide Cancer Research, UK survival rates for cancer have doubled since the 1970s.

Some cancers, such as leukaemia and testicular cancer, have made particularly impressive jumps. In the 1970s only about 5% of people survived their leukaemia diagnosis for ten years or longer, now almost 50% do. The ten-year survival rate for testicular cancer is now at 91% – an amazing improvement.

But there is still a long way to go. There are still cancers that have seen hardly any improvement in survival rates over the years, including lung, pancreatic and oesophageal cancer.

Because of research, we now know more than ever before about the fundamental biology of cancer. It is this knowledge that is beginning to inform the design and development of brand-new treatments that seek to target the individuality of cancer. Progress so far has been fantastic, and we must push on in order to find ways to close the gap in survival rates for different cancers.

How do you ensure you fund only the most innovative and promising research into cancer around the world?

Since we last spoke, we have refined our Research Strategy to help guide our Scientific Advisory Committee in their decision on what to fund at our annual Big Ideas Gathering. Because we are restricted in how many projects we are currently able to fund, we want to make sure we are picking the best ideas of the bunch. Our remit hasn’t changed – to fund the best discovery research into new ways to prevent, diagnose and treat cancer – but we have made it clearer that we are looking for truly innovative and creative ideas that have the potential to transform our understanding of cancer.

This year, our process starts in February, when our annual grant round opens, and we invite applications from scientists all over the world. Once these are in, our Scientific Advisory Committee gets to work, selecting the applications that meet the criteria of our Research Strategy. These projects are then sent out for peer review by external experts in cancer research before the final decision is made by the Scientific Advisory Committee at our annual Big Ideas Gathering held in October.

What would you say is Worldwide Cancer Research’s biggest achievement to date?

We’ve been funding research for over 40 years so there are many success stories that we know of. The interesting thing is that because we fund truly new ideas, those right at the start of the research journey, it can take years or even decades before we know that breakthroughs made on a project are having a positive impact on the lives of people with cancer.

Out of all of them, I’d say our biggest achievement to date has been our involvement in starting the development of the cancer drug called olaparib – the first-in-class PARP inhibitor. The foundations came from a set of projects we funded with Professor Steve Jackson in Cambridge back in the 1990s and Professor Jackson then took his findings from those projects and went on to develop olaparib.

To this day, olaparib has been used to treat 30,000 people worldwide with certain ovarian, breast, pancreatic and prostate cancers. And research is still ongoing, with the drug now being tested in clinical trials for many different types of cancer.

What are the biggest challenges now facing cancer research and how will Worldwide Cancer Research overcome them?

Peering into a crystal ball when it comes to scientific advances is never easy. The exploratory nature of research means you can never really guess where the next big step is coming from and so it is probably best to resist making any grand predictions! I would guess that the trend towards personalised medicine will continue to gradually figure out which cancer patients will benefit most from which cancer drugs. And that immunotherapy – drugs and cell therapies that harness the power of the body’s own immune system to attack cancer – will become a mainstay of treatment for more and more types of cancer.

But those guesses are based on things we already know. Science already done. Worldwide Cancer Research exists to discover the new things, to start new trends and new lines of research that we probably couldn’t even guess at yet. History tells us that new ways to prevent, diagnose and treat cancer are rooted in fundamental discoveries made in the lab – often from scientists exploring how cancer works at its most basic level. That’s why it’s so important that we continue to fund these innovative new ideas. You really don’t know where they could lead in the future – and how many lives they could save.


Want to republish our articles?


We encourage all formats of sharing and republishing of our articles. Whether you want to host on your website, publication or blog, we welcome this. Find out more

Creative Commons Licence
(CC BY 4.0)

This work is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium or format

Adapt: You can change, and build upon the material for any purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the license, and indicate if changes were made.

More articles you may like

Professor Michael Ryan | What the Ugandan Response to HIV/AIDS Can Teach Us About Collaborative Governance

Professor Michael Ryan | What the Ugandan Response to HIV/AIDS Can Teach Us About Collaborative Governance

Persistent problems such as poverty, disease and hunger are of critical interest to organisation and management scholars. Developing countries often struggle with intractable social issues, including susceptibility to epidemics. The complexity of these challenges means it can be difficult for leaders to organise governance and ensure that resources and capabilities are effectively coordinated. Professor Michael Ryan looks at the case study of the HIV/AIDS response in Uganda, and asks how this can contribute to our understanding of public organisation and state capacity. In particular, he explores how Uganda was successful in using collaborative governance to manage the HIV/AIDS crisis.

Professor Aaron Brown | Brown Adipose Tissue and Optogenetics – The Next Step in Obesity Treatment?

Professor Aaron Brown | Brown Adipose Tissue and Optogenetics – The Next Step in Obesity Treatment?

Adipose tissue is more commonly known as body fat. Unlike white adipose tissue, which is linked to negative cardiovascular outcomes such as metabolic syndrome, brown adipose tissue is positively related to health and may reduce the risk of cardiometabolic diseases. Professor Aaron Brown and his team at the MaineHealth Institute for Research are working to understand brown adipose tissue regulation and explore its therapeutic potential. They have already made significant advancements through the application of optogenetics, a cutting-edge technique that harnesses the power of light to precisely manipulate specific cellular processes.

Dr Kimberly Kay Hoang | Who Gets to Be a Theorist? The Oppression of Marginal Theories

Dr Kimberly Kay Hoang | Who Gets to Be a Theorist? The Oppression of Marginal Theories

Who gets to be a theorist? What kinds of theoretical work get marginalised in academic research? And how does this oppression play out in the peer-review process? Dr Kimberly Kay Hoang is a Professor of Sociology at the University of Chicago. She has explored how difficult it is to get your sociology research published if you are not using research deemed to be legitimate by reviewers. She brings awareness to these issues and argues for change amongst scholars so that new forms of knowledge are not missed, especially regarding feminist, minority and racial theories.

Dr Kimberly Kay Hoang | Spiderweb Capitalism: The Secret Financial Webs Built by the Ultra-Wealthy

Dr Kimberly Kay Hoang | Spiderweb Capitalism: The Secret Financial Webs Built by the Ultra-Wealthy

The anonymous leak of the Panama Papers in 2016 revealed how the exceptionally wealthy (such as politicians, celebrities and business leaders) hide their money and exploit secretive offshore tax regimes. Dr Kimberly Kay Hoang is a Professor of Sociology at the University of Chicago, and after six years of research, hundreds of interviews and travelling 350,000 miles, she published Spiderweb Capitalism: How Global Elites Exploit Frontier Markets. She uncovered the mechanisms behind the movement of money into and out of Southeast Asia, and how that money travels all over the world.